Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions.
Hayley F NorthJason BruggemannVanessa CropleyVaidy SwaminathanSuresh SundramRhoshel LenrootAvril M PereiraAndrew ZaleskyChad BousmanChristos PantelisThomas W WeickertCynthia Shannon WeickertPublished in: European archives of psychiatry and clinical neuroscience (2021)
While the biological substrates of brain and behavioural changes in persons with schizophrenia remain unclear, increasing evidence implicates that inflammation is involved. In schizophrenia, including first-episode psychosis and anti-psychotic naïve patients, there are numerous reports of increased peripheral inflammation, cognitive deficits and neuropathologies such as cortical thinning. Research defining the relationship between inflammation and schizophrenia symptomatology and neuropathology is needed. Therefore, we analysed the level of C-reactive protein (CRP), a peripheral inflammation marker, and its relationship with cognitive functioning in a cohort of 644 controls and 499 schizophrenia patients. In a subset of individuals who underwent MRI scanning (99 controls and 194 schizophrenia cases), we tested if serum CRP was associated with cortical thickness. CRP was significantly increased in schizophrenia patients compared to controls, co-varying for age, sex, overweight/obesity and diabetes (p < 0.006E-10). In schizophrenia, increased CRP was mildly associated with worse performance in attention, controlling for age, sex and education (R =- 0.15, p = 0.001). Further, increased CRP was associated with reduced cortical thickness in three regions related to attention: the caudal middle frontal, the pars opercularis and the posterior cingulate cortices, which remained significant after controlling for multiple comparisons (all p < 0.05). Together, these findings indicate that increased peripheral inflammation is associated with deficits in cognitive function and brain structure in schizophrenia, especially reduced attention and reduced cortical thickness in associated brain regions. Using CRP as a biomarker of peripheral inflammation in persons with schizophrenia may help to identify vulnerable patients and those that may benefit from adjunctive anti-inflammatory treatments.
Keyphrases
- bipolar disorder
- end stage renal disease
- oxidative stress
- ejection fraction
- chronic kidney disease
- newly diagnosed
- type diabetes
- metabolic syndrome
- healthcare
- peritoneal dialysis
- working memory
- emergency department
- cardiovascular disease
- insulin resistance
- magnetic resonance imaging
- adipose tissue
- high resolution
- weight gain
- patient reported outcomes
- body mass index
- patient reported
- quality improvement
- blood brain barrier
- contrast enhanced
- high fat diet induced
- electronic health record